Lantheus Holdings (LNTH) Non-Current Assets (2014 - 2026)
Lantheus Holdings (LNTH) posted quarterly Non-Current Assets of $1.4 billion for Q1 2026, up 122.39% year-over-year from $631.4 million in Q1 2025, and up 5.79% quarter-over-quarter from $1.3 billion in Q4 2025.
Lantheus Holdings (LNTH) Non-Current Assets (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has reported Non-Current Assets for 13 consecutive years, with $1.4 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets rose 122.39% year-over-year to $1.4 billion; the TTM figure through Mar 2026 stood at $5.0 billion (up 81.87% YoY), while the FY2025 annual figure was $1.3 billion, up 103.06% from the prior year.
- Non-Current Assets climbed to $1.4 billion in Q1 2026 per LNTH's latest filing, from $1.3 billion in the prior quarter.
- Across five years, Non-Current Assets topped out at $1.4 billion in Q1 2026 and bottomed at $565.3 million in Q4 2023.
- Historically, Non-Current Assets has averaged $775.5 million across 5 years, with a median of $643.6 million in 2022.
- Annual changes were most pronounced in 2023 — Non-Current Assets decreased 12.17% — and 2026, when it soared 122.39%.
- Lantheus Holdings' Non-Current Assets stood at $643.6 million in 2022, then slipped by 12.17% to $565.3 million in 2023, then climbed by 15.63% to $653.7 million in 2024, then surged by 103.06% to $1.3 billion in 2025, then climbed by 5.79% to $1.4 billion in 2026.
- Business Quant data shows LNTH's Non-Current Assets at $1.4 billion in Q1 2026, $1.3 billion in Q4 2025, and $1.4 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 2.96 Bn |
| 10 | Lantheus Holdings | 6.54 Bn | 5.94 Bn | 241.86 Mn | 1.39 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.39 Bn |
| Mar 31, 2026 | 1.40 Bn |
| Dec 31, 2025 | 1.33 Bn |
| Sep 30, 2025 | 1.35 Bn |
| Jun 30, 2025 | 914.26 Mn |
| Mar 31, 2025 | 631.44 Mn |
| Dec 31, 2024 | 653.71 Mn |
| Sep 30, 2024 | 753.92 Mn |
| Jun 30, 2024 | 708.69 Mn |
| Mar 31, 2024 | 682.53 Mn |
| Dec 31, 2023 | 565.33 Mn |
| Sep 30, 2023 | 573.18 Mn |
| Jun 30, 2023 | 585.50 Mn |
| Mar 31, 2023 | 576.01 Mn |
| Dec 31, 2022 | 643.64 Mn |
| Sep 30, 2022 | 594.04 Mn |
| Jun 30, 2022 | 609.40 Mn |
| Mar 31, 2022 | 608.42 Mn |
| Dec 31, 2021 | 627.99 Mn |
| Sep 30, 2021 | 646.30 Mn |